BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products? Expert Rev Hematol 2019;12:1-13. [PMID: 31282771 DOI: 10.1080/17474086.2018.1564032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study. J Clin Endocrinol Metab 2022;107:e2717-28. [PMID: 35405011 DOI: 10.1210/clinem/dgac220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Escobar M, Mancuso ME, Hermans C, Leissinger C, Seifert W, Li Y, McKeand W, Oldenburg J. IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data. J Clin Med 2022;11:1071. [PMID: 35207344 DOI: 10.3390/jcm11041071] [Reference Citation Analysis]
3 Coppola A, Franchini M, Pappagallo G, Borchiellini A, De Cristofaro R, Molinari AC, Santoro RC, Santoro C, Tagliaferri A. Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. J Clin Med 2022;11:801. [PMID: 35160253 DOI: 10.3390/jcm11030801] [Reference Citation Analysis]
4 Jair Lara-navarro I, Rebeca Jaloma-cruz A. Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. Tohoku J Exp Med 2022;256:197-207. [DOI: 10.1620/tjem.256.197] [Reference Citation Analysis]
5 Bonanad S, Núñez R, Poveda JL, Kurnik K, Goldmann G, Andreozzi V, Vandewalle B, Santos S. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A. Adv Ther 2021;38:4872-84. [PMID: 34368918 DOI: 10.1007/s12325-021-01853-0] [Reference Citation Analysis]
6 Burke T, Asghar S, O'Hara J, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet J Rare Dis 2021;16:143. [PMID: 33743752 DOI: 10.1186/s13023-021-01774-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Miesbach W, Berntorp E. Translating the success of prophylaxis in haemophilia to von Willebrand disease. Thromb Res 2021;199:67-74. [PMID: 33445035 DOI: 10.1016/j.thromres.2020.12.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Graf L, Yan S, Shen MC, Balasa V. A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. J Med Econ 2020;23:1493-8. [PMID: 32969738 DOI: 10.1080/13696998.2020.1828092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chowdary P. Extended half-life recombinant products in haemophilia clinical practice - Expectations, opportunities and challenges. Thromb Res 2020;196:609-17. [PMID: 31883700 DOI: 10.1016/j.thromres.2019.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]